Pharming Group N.V.
Business
Pharming Group N.V. is a global biopharmaceutical company focused on developing and commercializing therapies for rare, debilitating and life‑threatening diseases. It commercializes RUCONEST® (a recombinant C1 esterase inhibitor) and Joenja® (leniolisib), and advances a pipeline including KL1333 for primary mitochondrial disease and additional leniolisib indications. Key business divisions include commercial operations, research and development (clinical programs and preclinical assets), and manufacturing based on a proprietary transgenic production platform and outsourced CMOs. Products are marketed directly in the United States, the United Kingdom and the European Economic Area, with additional distribution and access programs across other international markets.
Summary from filing dated 2025-04-03
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $2.54M |
| Total assets | $499.96M |
| Total liabilities | — |
| Stockholders' equity | — |
| Operating cash flow | — |